Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report)'s stock price shot up 5.7% during trading on Monday . The company traded as high as $2.99 and last traded at $2.98. 528,928 shares traded hands during mid-day trading, a decline of 33% from the average session volume of 785,477 shares. The stock had previously closed at $2.82.
Wall Street Analysts Forecast Growth
Separately, Cormark raised shares of Curaleaf from a "hold" rating to a "moderate buy" rating in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, According to MarketBeat, the company currently has a consensus rating of "Strong Buy".
Read Our Latest Stock Analysis on Curaleaf
Curaleaf Stock Down 2.1%
The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.70 and a current ratio of 1.47. The business has a 50-day simple moving average of $1.70 and a two-hundred day simple moving average of $1.21. The company has a market capitalization of $2.21 billion, a price-to-earnings ratio of -10.31 and a beta of 0.69.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. Curaleaf had a negative return on equity of 14.61% and a negative net margin of 18.08%. As a group, equities analysts predict that Curaleaf Holdings, Inc. will post -0.25 EPS for the current year.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Further Reading
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.